Cargando…
The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity
AIMS: Tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverse events. So far, the Systematic Coronary Risk Evaluation (SCORE) charts of the European Society of Cardiology (ESC) have been used to identify cancer patients at increased cardiovasc...
Autores principales: | Di Lisi, Daniela, Madaudo, Cristina, Alagna, Giulia, Santoro, Marco, Rossetto, Ludovico, Siragusa, Sergio, Novo, Giuseppina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065844/ https://www.ncbi.nlm.nih.gov/pubmed/35355425 http://dx.doi.org/10.1002/ehf2.13897 |
Ejemplares similares
-
Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review
por: Santoro, Marco, et al.
Publicado: (2021) -
Contractile Reserve in Heart Failure with Preserved Ejection Fraction
por: Di Lisi, Daniela, et al.
Publicado: (2022) -
Prognostic Impact of the HFA-PEFF Score in Patients with Acute Myocardial Infarction and an Intermediate to High HFA-PEFF Score
por: Lee, Kwan Yong, et al.
Publicado: (2022) -
An Evaluation of Levalbuterol HFA in the Prevention of Exercise-Induced Bronchospasm
por: Pearlman, D.S., et al.
Publicado: (2007) -
Smoking and the risk of acute myeloid leukaemia in cytogenetic subgroups
por: Moorman, A V, et al.
Publicado: (2002)